AI driven oncology Capitalize on Lantern Pharma's focus on AI-driven precision oncology and RADR platform to position value in enabling patient stratification and faster, more successful clinical trials for oncology partners and drug developers.

Multi-agent platform Leverage Open-Medicine AI and the evolving multi-agentic platform to offer end-to-end therapeutic development collaboration, appealing to pharma companies seeking integrated AI-assisted discovery, trial design, and data analysis.

Indication expansion Target opportunities around STAR-001 and pediatric CNS tumor programs as proof points for ADR management and regulatory progress, aligning with partners interested in orphan/rare disease and pediatric oncology collaborations.

Global AI hub Promote Lantern’s expansion of AI operations with a Bengaluru, India AI Center of Excellence to attract regional partnerships, CROs, and pharma co-development deals seeking cost-effective, high-throughput AI capabilities.

Finite resources Highlight the company’s lean size (11-50 employees) and established funding to identify partners open to flexible collaboration models, licensing, or milestone-based deals that leverage Lantern’s novel mechanisms and computational platforms.